Exondys 51

This page shows the latest Exondys 51 news and features for those working in and with pharma, biotech and healthcare.

Duchenne UK backs Evox dystrophin delivery project

At the moment that includes already-market drugs that skip over or ignore the mutation in the dystrophin gene – such as PTC Therapeutics’ Translarna (ataluren) and Sarepta’s Exondys 51 (eteplirsen) –

Latest news

CHMP backs Spark’s Luxturna, but rejects Sarepta again

Eteplirsen was approved in the US as Exondys 51 in 2016, although the decision came after FDA reviewers recommended that the drug be rejected as the evidence for its benefits was ... which there was no meaningful difference between Exondys and placebo in
Pfizer abandons antibody for Duchenne

News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics
Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Sarepta has made its name by launching the first ever FDA approved treatment for Duchenne muscular dystrophy, Exondys 51, and is now looking to expand its pipeline into other rare disease ... Sarepta has also just announced rising sales of Exondys 51,
Mallinckrodt doses first patient in muscular dystrophy trial

For now, the only approved therapies are Sarepta’s exon-skipping therapy Exondys 51 (eteplirsen), which has some controversy over its efficacy, PTC’s Translarna (ataluren), which is available in Europe
Summit plunges after Duchenne disappointment

Sarepta's investment in the field has been possible thanks to the FDA’s approval of the first US-approved Duchenne drug, Exondys 51, in 2016, despite controversies over its efficacy. ... The field is marked by the curiosity of the EMA having approved

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Alnylam can take heart in exceptions, however, such as Sarepta, with its Duchenne treatment Exondys 51, and hope it too can buck this trend.
Europe vs the US: New drug product approvals

Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US
Deal Watch February 2017

Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Medical Writer: Competitive salary and benefits

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Director – Healthcare PR: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Senior Medical Writer: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

PR Associate Director – Consumer Health & Beauty: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Account Director, Medical Education: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Subscribe to our email news alerts

PMHub

Add my company

Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...